Jacobson TA - Search Results

1

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results.

Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Mehta C, Mukherjee R, Ballantyne CM, Chung MK; REDUCE-IT Investigators. Olshansky B, et al. Among authors: jacobson ta. Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e61-e63. doi: 10.1093/ehjcvp/pvaa118. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 33010162 Free PMC article. No abstract available.

2

Maximizing the cost-effectiveness of lipid-lowering therapy.

Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Jacobson TA, et al. Arch Intern Med. 1998 Oct 12;158(18):1977-89. doi: 10.1001/archinte.158.18.1977. Arch Intern Med. 1998. PMID: 9778197 Review.

3

Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM. Jacobson TA, et al. Arch Intern Med. 2000 May 8;160(9):1361-9. doi: 10.1001/archinte.160.9.1361. Arch Intern Med. 2000. PMID: 10809042

4

Characteristics of US adults with the metabolic syndrome and therapeutic implications.

Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, Gause D, Varas C, Ballantyne CM. Jacobson TA, et al. Diabetes Obes Metab. 2004 Sep;6(5):353-62. doi: 10.1111/j.1462-8902.2004.00354.x. Diabetes Obes Metab. 2004. PMID: 15287928

5

Hypertriglyceridemia and cardiovascular risk reduction.

Jacobson TA, Miller M, Schaefer EJ. Jacobson TA, et al. Clin Ther. 2007 May;29(5):763-777. doi: 10.1016/j.clinthera.2007.05.002. Clin Ther. 2007. PMID: 17697898 Review.

6

The importance of non-HDL cholesterol reporting in lipid management.

Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-HDL Cholesterol. Blaha MJ, et al. Among authors: jacobson ta. J Clin Lipidol. 2008 Aug;2(4):267-73. doi: 10.1016/j.jacl.2008.06.013. Epub 2008 Jun 28. J Clin Lipidol. 2008. PMID: 21291742

7

Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.

Cohen JD, Brinton EA, Ito MK, Jacobson TA. Cohen JD, et al. Among authors: jacobson ta. J Clin Lipidol. 2012 May-Jun;6(3):208-15. doi: 10.1016/j.jacl.2012.03.003. J Clin Lipidol. 2012. PMID: 22658145 Free article.

8

Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education.

Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Wei MY, et al. Among authors: jacobson ta. J Clin Lipidol. 2013 Sep-Oct;7(5):472-83. doi: 10.1016/j.jacl.2013.03.001. Epub 2013 Mar 13. J Clin Lipidol. 2013. PMID: 24079289

9

Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study.

Ito MK, Maki KC, Brinton EA, Cohen JD, Jacobson TA. Ito MK, et al. Among authors: jacobson ta. J Clin Lipidol. 2014 Jan-Feb;8(1):69-76. doi: 10.1016/j.jacl.2013.10.006. Epub 2013 Nov 9. J Clin Lipidol. 2014. PMID: 24528687

10

Metabolic syndrome is associated with muscle symptoms among statin users.

Brinton EA, Maki KC, Jacobson TA, Sponseller CA, Cohen JD. Brinton EA, et al. Among authors: jacobson ta. J Clin Lipidol. 2016 Jul-Aug;10(4):1022-1029. doi: 10.1016/j.jacl.2016.05.003. Epub 2016 May 17. J Clin Lipidol. 2016. PMID: 27578135

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters